XAIR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -697.4% compared to Beyond Air's net margin of -49.65%. Beyond Air's return on equity of -218.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 1288.89%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Beyond Air has higher upside potential than NovaBay Pharmaceuticals, analysts believe Beyond Air is more attractive than NovaBay Pharmaceuticals.

Beyond Air has a beta of 0.221, which suggesting that the stock is 77.879% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Beyond Air quarterly revenues are $1.2M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Beyond Air's net income of -$8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Beyond Air's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 2.96x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -697.4% compared to Beyond Air's net margin of --. Beyond Air's return on equity of -218.07% beat Oragenics's return on equity of --.

Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 1288.89%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Beyond Air, analysts believe Oragenics is more attractive than Beyond Air.

Beyond Air has a beta of 0.221, which suggesting that the stock is 77.879% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Beyond Air quarterly revenues are $1.2M, which are larger than Oragenics quarterly revenues of --. Beyond Air's net income of -$8M is lower than Oragenics's net income of -$2.2M. Notably, Beyond Air's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 2.96x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -697.4% compared to Beyond Air's net margin of -35.79%. Beyond Air's return on equity of -218.07% beat Protalix BioTherapeutics's return on equity of 10.9%.

Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 1288.89%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Beyond Air has higher upside potential than Protalix BioTherapeutics, analysts believe Beyond Air is more attractive than Protalix BioTherapeutics.

Beyond Air has a beta of 0.221, which suggesting that the stock is 77.879% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Beyond Air quarterly revenues are $1.2M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Beyond Air's net income of -$8M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Beyond Air's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 2.96x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -697.4% compared to Beyond Air's net margin of --. Beyond Air's return on equity of -218.07% beat Theriva Biologics's return on equity of --.

Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 1288.89%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Beyond Air, analysts believe Theriva Biologics is more attractive than Beyond Air.

Beyond Air has a beta of 0.221, which suggesting that the stock is 77.879% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Beyond Air quarterly revenues are $1.2M, which are larger than Theriva Biologics quarterly revenues of --. Beyond Air's net income of -$8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Beyond Air's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 2.96x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.